CL2021000153A1 - Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 - Google Patents

Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1

Info

Publication number
CL2021000153A1
CL2021000153A1 CL2021000153A CL2021000153A CL2021000153A1 CL 2021000153 A1 CL2021000153 A1 CL 2021000153A1 CL 2021000153 A CL2021000153 A CL 2021000153A CL 2021000153 A CL2021000153 A CL 2021000153A CL 2021000153 A1 CL2021000153 A1 CL 2021000153A1
Authority
CL
Chile
Prior art keywords
interleukin
inhibitors
activity
compounds
sulfonimidamide
Prior art date
Application number
CL2021000153A
Other languages
English (en)
Inventor
Matthew Volgraf
Craig Stivala
Christopher Mcbride
Lynnie Lin Trzoss
Amogh Boloor
Nadezda Sokolova
Richard M Pastor
Steven Thomas Staben
Sarah M Bronner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021000153A1 publication Critical patent/CL2021000153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a novedosos compuestos de sulfonimidamida y compuestos relacionados y a su uso en el tratamiento de un trastorno que responde a la modulación de citocinas como IL-1β e IL-18, a la modulación de NLRP3 o a la inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio. (I)
CL2021000153A 2018-07-20 2021-01-19 Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 CL2021000153A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701313P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
CL2021000153A1 true CL2021000153A1 (es) 2021-07-09

Family

ID=67659954

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000153A CL2021000153A1 (es) 2018-07-20 2021-01-19 Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1

Country Status (20)

Country Link
US (1) US20210253596A1 (es)
EP (1) EP3823974A1 (es)
JP (1) JP7320595B2 (es)
KR (1) KR20210034596A (es)
CN (1) CN112513048A (es)
AR (1) AR115822A1 (es)
AU (1) AU2019306658A1 (es)
BR (1) BR112021001044A2 (es)
CA (1) CA3105521A1 (es)
CL (1) CL2021000153A1 (es)
CO (1) CO2021001530A2 (es)
CR (1) CR20210022A (es)
IL (1) IL279256A (es)
MA (1) MA53172A (es)
MX (1) MX2021000780A (es)
PE (1) PE20211811A1 (es)
PH (1) PH12021500005A1 (es)
SG (1) SG11202013062VA (es)
TW (1) TWI825134B (es)
WO (1) WO2020018975A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55695A (fr) 2017-01-23 2022-02-23 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
JP7411631B2 (ja) 2018-07-20 2024-01-11 エフ． ホフマン－ラ ロシュ アーゲー インターロイキン－１活性の阻害剤としてのスルホニル尿素化合物
EP3880659B1 (en) * 2018-11-16 2024-01-03 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
WO2020154499A1 (en) * 2019-01-23 2020-07-30 Novartis Inflammasome Research, Inc. Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (en) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
EP4059930A4 (en) 2019-11-12 2024-03-20 Chengdu Baiyu Pharmaceutical Co Ltd AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND ITS APPLICATION IN MEDICINE
KR20220131534A (ko) * 2020-01-22 2022-09-28 에프. 호프만-라 로슈 아게 Nlrp3 조절제로서의 술폰이미드아미드 화합물
IL296488A (en) 2020-03-16 2022-11-01 Zomagen Biosciences Ltd nlrp3 modulators
CN115485026A (zh) 2020-04-15 2022-12-16 詹森药业有限公司 Nlrp3炎体途径抑制剂吡唑并[1，2-d][1，2，4]三嗪-2-基-乙酰胺
BR112022020807A2 (pt) 2020-04-15 2022-11-29 Janssen Pharmaceutica Nv Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3
EP4139312A1 (en) 2020-04-23 2023-03-01 JANSSEN Pharmaceutica NV Tricyclic compounds as inhibitors of nlrp3
JP2023523756A (ja) 2020-04-30 2023-06-07 ヤンセン ファーマシューティカ エヌ．ベー． 新規なトリアジノインドール化合物
US20230202989A1 (en) 2020-05-28 2023-06-29 Janssen Pharmaceutica Nv Compounds
EP4168395A1 (en) 2020-06-19 2023-04-26 AC Immune SA Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway
JP2023542205A (ja) 2020-09-24 2023-10-05 ヤンセン ファーマシューティカ エヌ．ベー． 新規化合物
EP3974415A1 (en) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nlrp3 modulators
CN114539256B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
CA3208988A1 (en) 2021-03-04 2022-09-09 Daniel Oehlrich 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3
EP4301754A1 (en) 2021-03-04 2024-01-10 Janssen Pharmaceutica NV 4-amino-6-oxo-pyridazine derivatives modulating nlrp3
BR112023022471A2 (pt) 2021-04-29 2024-01-16 Janssen Pharmaceutica Nv Derivados de ftalazinona como inibidores de inflamassoma nlrp3
WO2022237781A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
TW202246230A (zh) * 2021-05-10 2022-12-01 大陸商成都百裕製藥股份有限公司 醯胺衍生物及其應用
EP4363418A1 (en) 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
IL308461A (en) * 2021-07-19 2024-01-01 Genentech Inc Sulfonimidamide compounds and their uses
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2024010772A1 (en) * 2022-07-06 2024-01-11 Kodiak Sciences Inc. Nlrp3 inhibitors
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds
WO2024064245A1 (en) 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881228T3 (es) * 2015-02-16 2021-11-29 Univ Queensland Sulfonilureas y compuestos relacionados y uso de los mismos
MA55695A (fr) * 2017-01-23 2022-02-23 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
PT3658539T (pt) * 2017-07-24 2024-04-26 Novartis Ag Compostos e composições para tratar condições associadas à atividade de nlrp
WO2019068772A1 (en) * 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS

Also Published As

Publication number Publication date
IL279256A (en) 2021-01-31
PE20211811A1 (es) 2021-09-14
US20210253596A1 (en) 2021-08-19
JP2021532101A (ja) 2021-11-25
JP7320595B2 (ja) 2023-08-03
EP3823974A1 (en) 2021-05-26
CA3105521A1 (en) 2020-01-23
CN112513048A (zh) 2021-03-16
TW202016078A (zh) 2020-05-01
WO2020018975A1 (en) 2020-01-23
TWI825134B (zh) 2023-12-11
CR20210022A (es) 2021-02-18
SG11202013062VA (en) 2021-02-25
CO2021001530A2 (es) 2021-03-08
PH12021500005A1 (en) 2021-09-13
AU2019306658A1 (en) 2021-01-07
KR20210034596A (ko) 2021-03-30
BR112021001044A2 (pt) 2021-04-13
MA53172A (fr) 2021-05-26
AR115822A1 (es) 2021-03-03
MX2021000780A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
CO2021001530A2 (es) Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
CO2019009036A2 (es) Compuestos químicos como inhibidores de la actividad de la interleuquina-1
CL2021000152A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
ECSP22012826A (es) Inhibidores de parp1
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
CO2022010241A2 (es) Inhibidores de sos1
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
CO2022004595A2 (es) Aminas bicíclicas como inhibidoras de la cdk2
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016000918A1 (es) Compuestos derivados de pirimidin amidas con actividad inhibidora del factor de crecimiento fgfr (fgfr4 y fgf19); composición farmacéutica que los comprende y uso en el tratamiento del carcinoma hepatocelular.
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
CL2019002557A1 (es) Pirimidopirimidinonas útiles como inhibidores de la quinasa wee-1.
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
CO2022012594A2 (es) Inhibidores del eif4e y sus usos
CL2019001397A1 (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
CL2019000572A1 (es) Compuesto de imida y uso del mismo.